A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer

Inclusion Criteria:

- Histologically confirmed non-low grade, non-borderline (low malignant potential)
ovarian, fallopian tube, or primary peritoneal cancer which has progressed after
paclitaxel / platinum-based therapy.

- Platinum-sensitive disease. Radiological progression must have occurred 6 months or
more after the completion of the most recent platinum-based treatment.

- Measurable disease.

- Available tumor sample(s).

- Performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) Performance
Scale.

- Adequate organ function.

Exclusion Criteria:

- Pregnancy or the intention to become pregnant during the course of the study.

- Participation in a study with an investigational compound or device within 28 days of
receiving first dose of study medication.

- Active central nervous system (CNS) metastases and/or carcinomatous meningitis.

- Primary CNS tumor.

- Known hypersensitivity or contraindications to the components of potential study
therapy (paclitaxel, carboplatin, MK-1775) or its analogs (i.e. cremophor, mannitol,
etc.).

- Participant requires the use of medications or products that are metabolized by, or
inhibit, or induce Cytochrome P450 3A (CYP3A4).

- Ongoing peripheral neuropathies ≥Grade 2 and related to previous treatment.

- Known psychiatric or substance abuse disorders.

- Regular use (including "recreational use") of any illicit drugs or recent history
(within the last year) of drug or alcohol abuse.

- HIV positive.

- Active Hepatitis B or C.

- Symptomatic ascites or pleural effusion.

- Clinical history suggestive of Li Fraumeni Syndrome.